Cover Image
市場調查報告書

美國的注射器及注射針市場分析

US Market Report for Syringes and Needles - MedCore

出版商 iData Research Inc. 商品編碼 360659
出版日期 內容資訊 英文 187 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的注射器及注射針市場分析 US Market Report for Syringes and Needles - MedCore
出版日期: 2016年05月01日 內容資訊: 英文 187 Pages
簡介

本報告提供美國的注射器及針頭的市場相關分析,市場背景情況 (相關疾病與其患病人數等) ,及整體整體市場規模的變化及預測 (過去4年、今後7年份),各產品詳細趨勢等調查、估計,主要企業簡介與產品結構,近幾年的企業間競爭情勢等資訊彙整,為您概述為以下內容。

摘要整理

分析方法

  • 分析範圍
  • IDATA的9階段的分析方法

疾病概要

  • 解剖學性的基礎結構
    • 人的血管系統
  • 血管的病理與疾病
    • 癌症
    • 末期腎功能衰竭 (末期腎臟疾病)
    • 糖尿病
  • 患者的人口組成
    • 癌症 (共15種)
    • 末期腎功能衰竭
      • 發病數量 (各種模式,各年齡層等)
      • 人工透析開始時使用的血管通路手段
      • 患病人數 (各種模式,各年齡層等)
    • 糖尿病
      • 受診完畢的成人發病數量 (各州)
      • 受診完畢的成人患病人數 (重症度別,各年齡層,男女,各州)

產品的評估

  • 產品系列
    • 注射器及注射針
      • 簡介
      • Allison Medical (共1項產品)
      • B. Braun (共2項產品)
      • Becton Dickinson (共11項產品)
      • Cardinal Health (共1項產品)
      • Delta Hi-Tech, Inc. (共1項產品)
      • Medical Plastic Devices, Inc. (共1項產品)
      • Medtronic (共2項產品)
      • MYCO Medical (共1項產品)
      • Nipro (共1項產品)
      • Novo Nordisk (共2項產品)
      • Owen Mumford, Inc. (共1項產品)
      • Perrigo (共1項產品)
      • Protectus Medical Devices (共1項產品)
      • ReliOn (共1項產品)
      • Retractable Technologies, Inc. (共2項產品)
      • Revolutions Medical (共1項產品)
      • Medical (共1項產品)
      • Smiths Medical (共1項產品)
      • SOL-MILLENNIUM (共3項產品)
      • STAT Medical Devices (共1項產品)
      • Terumo Corporation (共2項產品)
      • UltiCare (共1項產品)

注射器及注射針市場

  • 市場概要
  • 市場分析與預測
    • 注射器整體市場
      • 傳統注射器
      • 滑套安全注射器
      • 伸縮型安全注射器
      • 鉸鏈型安全注射器
      • 胰島素注射器
        • 個人胰島素注射器
        • 專家用胰島素注射器
    • 針頭整體市場
      • 傳統針頭
      • 隔離安全針頭
      • 旋轉式安全針頭
      • 胰島素筆針用針頭
  • 推動及阻礙市場要素
    • 推動市場要素
    • 阻礙市場要素
  • 競爭環境

圖表一覽

目錄
Product Code: iDATA_USVA16_MC_SN

The total U.S. market for syringes and needles comprises the syringe segment and the needle segment. The syringe segment comprises the conventional syringe, sliding sleeve safety syringe, retractable safety syringe, hinged safety syringe and insulin syringe sub-segments. The insulin syringe sub-segment includes insulin syringes sold in the personal and professional markets. The needle segment comprises the conventional needle, shielding safety needle, pivoting safety needle and insulin pen needle subsegments.

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

  • 1.1. U.S. VASCULAR ACCESS DEVICES AND ACCESSORIES MARKET OVERVIEW
  • 1.2. COMPETITIVE LANDSCAPE
  • 1.3. MARKET TRENDS
  • 1.4. KEY MARKET DEVELOPMENTS
  • 1.5. MARKETS INCLUDED
  • 1.6. PROCEDURES INCLUDED
  • 1.7. PROCEDURE CODES INVESTIGATED
  • 1.8. KEY REPORT UPDATES
  • 1.9. VERSION HISTORY

RESEARCH METHODOLOGY

  • 2.1. RESEARCH SCOPE
  • 2.2. IDATA'S 9-STEP METHODOLOGY
    • Step 1: Project Initiation & Team Selection
    • Step 2: Prepare Data Systems and Perform Secondary Research
    • Step 3: Preparation for Interviews & Questionnaire Design
    • Step 4: Performing Primary Research
    • Step 5: Research Analysis: Establishing Baseline Estimates
    • Step 6: Market Forecast and Analysis
    • Step 7: Identify Strategic Opportunities
    • Step 8: Final Review and Market Release
    • Step 9: Customer Feedback and Market Monitoring

DISEASE OVERVIEW

  • 3.1. BASIC ANATOMY
    • 3.1.1. Human Vascular System
  • 3.2. VASCULAR PATHOLOGY AND DISORDERS
    • 3.2.1. Cancer
    • 3.2.2. End-Stage Renal Disease
    • 3.2.3. Diabetes
  • 3.3. PATIENT DEMOGRAPHICS
    • 3.3.1. Cancer
      • 3.3.1.1. Digestive Cancer
      • 3.3.1.2. Genital Cancer
      • 3.3.1.3. Breast Cancer
      • 3.3.1.4. Respiratory Cancer
      • 3.3.1.5. Urinary Cancer
      • 3.3.1.6. Skin Cancer
      • 3.3.1.7. Lymphoma
      • 3.3.1.8. Endocrine System Cancer
      • 3.3.1.9. Leukemia
      • 3.3.1.10. Oral Cavity/Larynx
      • 3.3.1.11. Myeloma
      • 3.3.1.12. Brain/Other Nervous System
      • 3.3.1.13. Soft Tissue (including heart)
      • 3.3.1.14. Bones and Joints
      • 3.3.1.15. Eye and Orbit
    • 3.3.2. End-Stage Renal Disease
      • 3.3.2.1. End-Stage Renal Disease Incidence
        • 3.3.2.1.1. End-Stage Renal Disease Incident Cases by Modality
        • 3.3.2.1.2. End-Stage Renal Disease Incident Cases by Age Group
        • 3.3.2.1.3. End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy
      • 3.3.2.2. Vascular Access Use at Hemodialysis Initiation
        • 3.3.2.2.1. Vascular Access Use During First Year of Hemodialysis
          • 3.3.2.2.1.1. Vascular Access Use During First Year of Hemodialysis by Age Group
          • 3.3.2.2.1.2. Vascular Access Use During First Year of Hemodialysis by Sex
      • 3.3.2.3. End-Stage Renal Disease Prevalence
        • 3.3.2.3.1. End-Stage Renal Disease Prevalent Cases by Modality
          • 3.3.2.3.1.1. Prevalent Hemodialysis Patients by Vascular Access Type
        • 3.3.2.3.2. End-Stage Renal Disease Prevalent Cases by Age Group
        • 3.3.2.3.3. End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy
  • 3.3.3. Diabetes
    • 3.3.3.1. Diagnosed Diabetes Incidence Amongst Adults
      • 3.3.3.1.1. Diagnosed Diabetes Incidence Amongst Adults by State
    • 3.3.3.2. Diagnosed Diabetes Prevalence Amongst Adults
      • 3.3.3.2.1. Diagnosed Diabetes Prevalence Amongst Adults by Medication Status
      • 3.3.3.2.2. Diagnosed Diabetes Prevalence Amongst Adults by State and Age Group
      • 3.3.3.2.3. Diagnosed Diabetes Prevalence Amongst Adults by State and Gender

PRODUCT ASSESSMENT

  • 4.1. PRODUCT PORTFOLIOS
    • 4.1.1. Syringe and Needles
      • 4.1.1.1. Introduction
      • 4.1.1.2. Allison Medical
        • 4.1.1.2.1. SureComfort™
      • 4.1.1.3. B. Braun
        • 4.1.1.3.1. Injekt®
        • 4.1.1.3.2. Other Syringe & Needle Offerings
      • 4.1.1.4. Becton Dickinson
        • 4.1.1.4.1. BD™ Insulin Syringes
        • 4.1.1.4.2. BD™ Allergy Syringes
        • 4.1.1.4.3. BD™ Tuberculin Syringes
        • 4.1.1.4.4. BD™ Syringes & Needles
        • 4.1.1.4.5. BD PrecisionGlide™ Needles
        • 4.1.1.4.6. BD Safety-Lok™ Syringes
        • 4.1.1.4.7. BD SafetyGlide™ Syringes & Needles
        • 4.1.1.4.8. BD Eclipse™ Needles and Syringes
        • 4.1.1.4.9. BD Integra™ Needles and Syringes
        • 4.1.1.4.10. BD AutoShield™
        • 4.1.1.4.11. Ultra-Fine™
      • 4.1.1.5. Cardinal Health
        • 4.1.1.5.1. Cardinal Health™
      • 4.1.1.6. Delta Hi-Tech, Inc.
        • 4.1.1.6.1. AIMSCO®
      • 4.1.1.7. Medical Plastic Devices, Inc.
        • 4.1.1.7.1. Insupen®
      • 4.1.1.8. Medtronic
        • 4.1.1.8.1. Magellan™
        • 4.1.1.8.2. Monoject™
      • 4.1.1.9. MYCO Medical
        • 4.1.1.9.1. Dispovan®
      • 4.1.1.10. Nipro Medical
        • 4.1.1.10.1. Nipro™
      • 4.1.1.11. Novo Nordisk
        • 4.1.1.11.1. NovoFine®
        • 4.1.1.11.2. NovoTwist®
      • 4.1.1.12. Owen Mumford, Inc.
        • 4.1.1.12.1. Unifine®
      • 4.1.1.13. Perrigo
        • 4.1.1.13.1. Clickfine®
      • 4.1.1.14. Protectus Medical Devices
        • 4.1.1.14.1. Protectus®
      • 4.1.1.15. ReliOn
        • 4.1.1.15.1. ReliOn®
      • 4.1.1.16. Retractable Technologies, Inc.
        • 4.1.1.16.1. VanishPoint®
        • 4.1.1.16.2. Patient Safe®
      • 4.1.1.17. Revolutions Medical
        • 4.1.1.17.1. ReVac™ Safety 1st
      • 4.1.1.18. Medical
        • 4.1.1.18.1. Safe-1®
      • 4.1.1.19. Smiths Medical
        • 4.1.1.19.1. Needle-Pro®
      • 4.1.1.20. SOL-MILLENNIUM
        • 4.1.1.20.1. SOL-CARE®
        • 4.1.1.20.2. SOL-M™
        • 4.1.1.20.3. SOL-GUARD™
      • 4.1.1.21. STAT Medical Devices
        • 4.1.1.21.1. Super-Fine™
      • 4.1.1.22. Terumo
        • 4.1.1.22.1. SurGuard®
        • 4.1.1.22.2. TERUMO®
      • 4.1.1.23. UltiCare
        • 4.1.1.23.1. UltiCare®

SYRINGE & NEEDLE MARKET

  • 5.1. MARKET OVERVIEW
  • 5.2. MARKET ANALYSIS AND FORECAST
    • 5.2.1. Total Syringe Market
      • 5.2.1.1. Conventional Syringe Market
      • 5.2.1.2. Sliding Sleeve Safety Syringe Market
      • 5.2.1.3. Retractable Safety Syringe Market
      • 5.2.1.4. Hinged Safety Syringe Market
      • 5.2.1.5. Insulin Syringe Market
        • 5.2.1.5.1.1. Personal Insulin Syringe Market
        • 5.2.1.5.1.2. Professional Insulin Syringe Market
    • 5.2.2. Total Needle Market
      • 5.2.2.1. Conventional Needle Market
      • 5.2.2.2. Shielding Safety Needle Market
      • 5.2.2.3. Pivoting Safety Needle Market
      • 5.2.2.4. Insulin Pen Needle Market
  • 5.3. DRIVERS AND LIMITERS
    • 5.3.1. Market Drivers
    • 5.3.2. Market Limiters
  • 5.4. COMPETITIVE MARKET SHARE ANALYSIS

LIST OF CHARTS

  • Chart 0-1: Vascular Access Device Market by Segment, U.S., 2012-2022
  • Chart 0-2: Vascular Access Device Market Overview, U.S., 2015 and 2022
  • Chart 3-1: Male Incidence, Digestive Cancer, U.S., 2016
  • Chart 3-2: Male Deaths, Digestive Cancer, U.S., 2016
  • Chart 3-3: Female Incidence, Digestive Cancer, U.S., 2016
  • Chart 3-4: Female Deaths, Digestive Cancer, U.S., 2016
  • Chart 3-5: Male Incidence, Genital Cancer, U.S., 2016
  • Chart 3-6: Male Deaths, Genital Cancer, U.S., 2016
  • Chart 3-7: Female Incidence, Genital Cancer, U.S., 2016
  • Chart 3-8: Female Deaths, Genital Cancer, U.S., 2016
  • Chart 3-9: Incidence by Gender, Breast Cancer, U.S., 2016
  • Chart 3-10: Deaths by Gender, Breast Cancer, U.S., 2016
  • Chart 3-11: Male Incidence, Respiratory Cancer, U.S., 2016
  • Chart 3-12: Male Deaths, Respiratory Cancer, U.S., 2016
  • Chart 3-13: Female Incidence, Respiratory Cancer, U.S., 2016
  • Chart 3-14: Female Deaths, Respiratory Cancer, U.S., 2016
  • Chart 3-15: Male Incidence, Urinary Cancer, U.S., 2016
  • Chart 3-16: Male Deaths, Urinary Cancer, U.S., 2016
  • Chart 3-17: Female Incidence, Urinary Cancer, U.S., 2016
  • Chart 3-18: Female Deaths, Urinary Cancer, U.S., 2016
  • Chart 3-19: Male Incidence, Skin Cancer, U.S., 2016
  • Chart 3-20: Male Deaths, Skin Cancer, U.S., 2016
  • Chart 3-21: Female Incidence, Skin Cancer, U.S., 2016
  • Chart 3-22: Female Deaths, Skin Cancer, U.S., 2016
  • Chart 3-23: Male Incidence, Lymphoma Cancer, U.S., 2016
  • Chart 3-24: Male Deaths, Lymphoma Cancer, U.S., 2016
  • Chart 3-25: Female Incidence, Lymphoma Cancer, U.S., 2016
  • Chart 3-26: Female Deaths, Lymphoma Cancer, U.S., 2016
  • Chart 3-27: Male Incidence, Endocrine Cancer, U.S., 2016
  • Chart 3-28: Male Deaths, Endocrine Cancer, U.S., 2016
  • Chart 3-29: Female Incidence, Endocrine Cancer, U.S., 2016
  • Chart 3-30: Female Deaths, Endocrine Cancer, U.S., 2016
  • Chart 3-31: Male Incidence, Leukemia Cancer, U.S., 2016
  • Chart 3-32: Male Deaths, Leukemia Cancer, U.S., 2016
  • Chart 3-33: Female Incidence, Leukemia Cancer, U.S., 2016
  • Chart 3-34: Female Deaths, Leukemia Cancer, U.S., 2016
  • Chart 3-35: Male Incidence, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-36: Male Deaths, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-37: Female Incidence, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-38: Female Deaths, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-39: Incidence by Gender, Myeloma Cancer, U.S., 2016
  • Chart 3-40: Deaths by Gender, Myeloma Cancer, U.S., 2016
  • Chart 3-41: Incidence by Gender, Brain/Other Nervous System Cancer, U.S., 2016
  • Chart 3-42: Deaths by Gender, Brain/Other Nervous System Cancer, U.S., 2016
  • Chart 3-43: Incidence by Gender, Soft Tissue Cancer, U.S., 2016
  • Chart 3-44: Deaths by Gender, Soft Tissue Cancer, U.S., 2016
  • Chart 3-45: Incidence by Gender, Bone and Joint Cancers, U.S., 2016
  • Chart 3-46: Deaths by Gender, Bone and Joint Cancers, U.S., 2016
  • Chart 3-47: Incidence by Gender, Eye and Orbit Cancers, U.S., 2016
  • Chart 3-48: Deaths by Gender, Eye and Orbit Cancers, U.S., 2016
  • Chart 3-49: End-Stage Renal Disease Incident Cases, U.S., 1996-2015
  • Chart 3-50: End-Stage Renal Disease Incident Cases by Modality, U.S., 1996-2015
  • Chart 3-51: End-Stage Renal Disease Incident Cases by Age Group, U.S., 1996-2015
  • Chart 3-52: End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy, U.S., 1996-2015 83
  • Chart 3-53: Vascular Access Use at Hemodialysis Initiation, U.S., 2005-2015
  • Chart 3-54: Vascular Access Use During First Year of Hemodialysis, U.S., 2013-2014
  • Chart 3-55: End-Stage Renal Disease Prevalent Case Count, U.S., 1996-2015
  • Chart 3-56: End-Stage Renal Disease Prevalent Cases by Modality, U.S., 1996-2015
  • Chart 3-57: Prevalent Hemodialysis Patients by Vascular Access Type, U.S., 2003-2015
  • Chart 3-58: End-Stage Renal Disease Prevalent Cases by Age Group, U.S., 1996-2015
  • Chart 3-59: End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Chart 3-60: Diagnosed Diabetes Incidence Count Adults, U.S., 1997-2015
  • Chart 3-61: Diagnosed Diabetes Prevalence Count Adults, U.S., 1997-2015
  • Chart 5-1: Syringe & Needle Market by Device Type, U.S., 2012-2022
  • Chart 5-2: Syringe & Needle Market Breakdown, U.S., 2015
  • Chart 5-3: Syringe & Needle Market Breakdown, U.S., 2022
  • Chart 5-4: Total Syringe Market, U.S., 2012-2022
  • Chart 5-5: Conventional Syringe Market, U.S., 2012-2022
  • Chart 5-6: Sliding Sleeve Safety Syringe Market, U.S., 2012-2022
  • Chart 5-7: Retractable Safety Syringe Market, U.S., 2012-2022
  • Chart 5-8: Hinged Safety Syringe Market, U.S., 2012-2022
  • Chart 5-9: Insulin Syringe Market, U.S., 2012-2022
  • Chart 5-10: Personal Insulin Syringe Market, U.S., 2012-2022
  • Chart 5-11: Professional Insulin Syringe Market, U.S., 2012-2022
  • Chart 5-12: Total Needle Market, U.S., 2012-2022
  • Chart 5-13: Conventional Needle Market, U.S., 2012-2022
  • Chart 5-14: Shielding Safety Needle Market, U.S., 2012-2022
  • Chart 5-15: Pivoting Safety Needle Market, U.S., 2012-2022
  • Chart 5-16: Insulin Pen Needle Market, U.S., 2012-2022
  • Chart 5-17: Leading Competitors, Syringe & Needle Market, U.S., 2015
  • Chart 5-18: Leading Competitors, Insulin Syringe & Pen Needle Market, U.S., 2015

LIST OF FIGURES

  • Figure 0-1: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, U.S., 2015 (1 of 2)
  • Figure 0-2: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, U.S., 2015 (2 of 2)
  • Figure 0-3: Companies Researched in Report, U.S., 2015
  • Figure 0-4: Factors Impacting the Vascular Access Device and Accessories Market by Segment, U.S.
  • Figure 0-5: Recent Events in the Vascular Access Device and Accessories Market, U.S., 2012-2015
  • Figure 0-6: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (1 of 3)
  • Figure 0-7: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (2 of 3)
  • Figure 0-8: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (3 of 3)
  • Figure 0-9: Vascular Access Devices & Accessories Procedures Covered, U.S., 2015
  • Figure 0-10: Procedural Codes, U.S., 2015
  • Figure 0-11: Key Report Updates, U.S., 2014 and 2016 (1 of 2)
  • Figure 0-12: Key Report Updates, U.S., 2014 and 2016 (2 of 2)
  • Figure 0-13: Version History
  • Figure 3-1: Digestive Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-2: Genital Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-3: Breast Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-4: Respiratory Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-5: Urinary Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-6: Skin Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-7: Lymphoma Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-8: Endocrine Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-9: Leukemia Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-10: Oral Cavity/Larynx Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-11: Myeloma Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-12: Brain/Other Nervous System Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-13: Soft Tissue (Including Heart) Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-14: Bone and Joint Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-15: Eye and Orbit Statistics by Type and Gender, U.S., 2016
  • Figure 3-16: End-Stage Renal Disease Incident Cases, U.S., 1996-2015
  • Figure 3-17: End-Stage Renal Disease Incident Cases by Modality, U.S., 1996-2015
  • Figure 3-18: End-Stage Renal Disease Incident Cases by Age Group, U.S., 1996-2015
  • Figure 3-19: End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Figure 3-20: Vascular Access Use at Hemodialysis Initiation, U.S., 2005-2015
  • Figure 3-21: Vascular Access Use During First Year of Hemodialysis, U.S., 2013-2014
  • Figure 3-22: Vascular Access Use During First Year of Hemodialysis by Age Group, U.S., 2013-2014
  • Figure 3-23: Vascular Access Use During First Year of Hemodialysis by Sex, U.S., 2013-2014
  • Figure 3-24: End-Stage Renal Disease Prevalent Case Count, U.S., 1996-2015
  • Figure 3-25: End-Stage Renal Disease Prevalent Cases by Modality, U.S., 1996-2015
  • Figure 3-26: Prevalent Hemodialysis Patients by Vascular Access Type, U.S., 2003-2015
  • Figure 3-27: End-Stage Renal Disease Prevalent Cases by Age Group, U.S., 1996-2015
  • Figure 3-28: End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Figure 3-29: Diagnosed Diabetes Incidence Count Adults, U.S., 1997-2015
  • Figure 3-30: Diagnosed Diabetes Incidence Age-Adjusted Rate per 1000 Adults by State, U.S., 2014 (1 of 2)
  • Figure 3-31: Diagnosed Diabetes Incidence Age-Adjusted Rate per 1000 Adults by State, U.S., 2014 (2 of 2)
  • Figure 3-32: Diagnosed Diabetes Prevalence Count Adults, U.S., 1997-2015
  • Figure 3-33: Diagnosed Diabetes Prevalence Count Adults by Medication Status, U.S., 1997-2015
  • Figure 3-34: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Age Group, U.S., 2014 (1 of 2)
  • Figure 3-35: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Age Group, U.S., 2014 (2 of 2)
  • Figure 3-36: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Gender, U.S., 2014 (1 of 2)
  • Figure 3-37: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Gender, U.S., 2014 (2 of 2)
  • Figure 5-1: Syringe & Needle Market by Device Type, U.S., 2012-2022 (US$M)
  • Figure 5-2: Total Syringe Market, U.S., 2012-2022
  • Figure 5-3: Conventional Syringe Market, U.S., 2012-2022
  • Figure 5-4: Sliding Sleeve Safety Syringe Market, U.S., 2012-2022
  • Figure 5-5: Retractable Safety Syringe Market, U.S., 2012-2022
  • Figure 5-6: Hinged Safety Syringe Market, U.S., 2012-2022
  • Figure 5-7: Insulin Syringe Market, U.S., 2012-2022
  • Figure 5-8: Personal Insulin Syringe Market, U.S., 2012-2022
  • Figure 5-9: Professional Insulin Syringe Market, U.S., 2012-2022
  • Figure 5-10: Total Needle Market, U.S., 2012-2022
  • Figure 5-11: Conventional Needle Market, U.S., 2012-2022
  • Figure 5-12: Shielding Safety Needle Market, U.S., 2012-2022
  • Figure 5-13: Pivoting Safety Needle Market, U.S., 2012-2022
  • Figure 5-14: Insulin Pen Needle Market, U.S., 2012-2022
  • Figure 5-15: Drivers and Limiters, Syringe & Needle Market, U.S., 2015
  • Figure 5-16: Leading Competitors, Syringe & Needle Market, U.S., 2015
  • Figure 5-17: Leading Competitors, Insulin Syringe & Pen Needle Market, U.S., 2015
Back to Top